| Outcome Measures: |
Primary: Incidence of adverse event (AE), serious adverse event (SAE), AE leading to study discontinuation, AE severity and relation with study drug, A summary of AEs and SAEs, AE leading to study discontinuation, AE severity and relation with study drug will be reported in the reported adverse events module, Time of Inform Consent Form to Day 29 (SAD) or Day 50 (MAD) | Secondary: Pharmacokinetics (PK): Cmax of HS-20094, PK: Cmax of HS-20094, Baseline to Day 22 (SAD) or Day 43 (MAD)|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of HS-20094, PK: AUC of HS-20094, Baseline to Day 22 (SAD) or Day 43 (MAD)|Pharmacokinetics (PK): Tmax of HS-20094, PK: Tmax of HS-20094, Baseline to Day 22 (SAD) or Day 43 (MAD)|Pharmacodynamics (PD): AUC of glucose, PD: AUC of glucose, Day 22 (MAD)|Pharmacodynamics (PD): AUC of insulin, PD: AUC of insulin, Day 22 (MAD)|Weight change, baseline to Day 29 (SAD) or Day 50 (MAD)
|
